ReviewViruses2020
Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target.
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 78 citations in OpenAlex.
- Correspondence on: "Targeting the HERV-K102 envelope elicits pyroptosis and represents a novel therapeutic strategy for acute myeloid leukemia".Blood research · 2026Article
- Nucleoside-Analog Reverse-Transcriptase Inhibitors (NRTIs) Against Multiple Sclerosis: Comprehensive Review on a Possible Novel Therapeutic Approach.Neurology international · 2026Review
- Identification of immunogenic neoantigens from intron retention in colorectal cancer.Scientific reports · 2026Article
- Oncogenic role of ERV with therapeutic potential.Frontiers in immunology · 2026Review
- The increased expression levels of human endogenous retrovirus-K envelope and human endogenous retrovirus-H polymerase transcripts in laryngeal squamous cell carcinoma.Virology journal · 2025Article
- Virotherapy as Gene Deliver for Anti-Cancer Therapy: A Review Article.Asian Pacific journal of cancer prevention : APJCP · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- Review
- Expression of LTR and LINE1 transposable elements defines atypical teratoid/rhabdoid tumor subtypes.Acta neuropathologica communications · 2025Article
- Article
- Exploring transposable elements: new horizons in cancer diagnostics and therapeutics.Mobile DNA · 2025Review
- Targeting HPV for the prevention, diagnosis, and treatment of cervical cancer.Journal of molecular cell biology · 2025Review
- Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- An integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis.Nucleic acids research · 2025Article
- Immunogenetics of longevity and its association with human endogenous retrovirus K.Frontiers in aging · 2025Article
- Expression profiles of TNF-Alpha and HERV-K Env proteins in multiple types of colon and lung disease.Genes & genomics · 2025Article
- The glioblastoma virome across tumor and extracellular compartments.Frontiers in oncology · 2025Article
- The role of HERV envelope protein in ovarian cancer.Frontiers in cell and developmental biology · 2025Review
- Characterization of novel human endogenous retrovirus structures on chromosomes 6 and 7.Frontiers in genetics · 2025Article
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
In diseases where epigenetic mechanisms are changed, such as cancer, many genes show altered gene expression and inhibited genes become activated. Human endogenous retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a class of neoantigens, and induce immune responses in different types of cancer. In this review, we describe the function of the HERV-K HML-2 subtype in carcinogenesis as biomarkers, and their potential as targets for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.